Literature DB >> 10780971

Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

H Bohets1, K Lavrijsen, J Hendrickx, J van Houdt, V van Genechten, P Verboven, W Meuldermans, J Heykants.   

Abstract

Cisapride is a prokinetic drug that is widely used to facilitate gastrointestinal tract motility. Structurally, cisapride is a substituted piperidinyl benzamide that interacts with 5-hydroxytryptamine-4 receptors and which is largely without central depressant or antidopaminergic side-effects. The aims of this study were to investigate the metabolism of cisapride in human liver microsomes and to determine which cytochrome P-450 (CYP) isoenzyme(s) are involved in cisapride biotransformation. Additionally, the effects of various drugs on the metabolism of cisapride were investigated. The major in vitro metabolite of cisapride was formed by oxidative N-dealkylation at the piperidine nitrogen, leading to the production of norcisapride. By using competitive inhibition data, correlation studies and heterologous expression systems, it was demonstrated that CYP3A4 was the major CYP involved. CYP2A6 also contributed to the metabolism of cisapride, albeit to a much lesser extent. The mean apparent K(m) against cisapride was 8.6+/-3.5 microM (n = 3). The peak plasma levels of cisapride under normal clinical practice are approximately 0.17 microM; therefore it is unlikely that cisapride would inhibit the metabolism of co-administered drugs. In this in vitro study the inhibitory effects of 44 drugs were tested for any effect on cisapride biotransformation. In conclusion, 34 of the drugs are unlikely to have a clinically relevant interaction; however, the antidepressant nefazodone, the macrolide antibiotic troleandomycin, the HIV-1 protease inhibitors ritonavir and indinavir and the calcium channel blocker mibefradil inhibited the metabolism of cisapride and these interactions are likely to be of clinical relevance. Furthermore, the antimycotics ketoconazole, miconazole, hydroxy-itraconazole, itraconazole and fluconazole, when administered orally or intravenously, would inhibit cisapride metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780971      PMCID: PMC1572003          DOI: 10.1038/sj.bjp.0703246

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

Review 1.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.

Authors:  F P Guengerich; T Shimada
Journal:  Chem Res Toxicol       Date:  1991 Jul-Aug       Impact factor: 3.739

2.  Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.

Authors:  P Dayer; T Leemann; R Striberni
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

3.  Effect of cisapride on morphine absorption after oral administration of sustained-release morphine.

Authors:  D J Rowbotham; K Milligan; P McHugh
Journal:  Br J Anaesth       Date:  1991-10       Impact factor: 9.166

Review 4.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 5.  Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease.

Authors:  B Ramirez; J E Richter
Journal:  Aliment Pharmacol Ther       Date:  1993-02       Impact factor: 8.171

6.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.

Authors:  W Tassaneeyakul; D J Birkett; M E Veronese; M E McManus; R H Tukey; L C Quattrochi; H V Gelboin; J O Miners
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

7.  Inhibition by fluoxetine of cytochrome P450 2D6 activity.

Authors:  S V Otton; D Wu; R T Joffe; S W Cheung; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

8.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

Authors:  L Pichard; I Fabre; G Fabre; J Domergue; B Saint Aubert; G Mourad; P Maurel
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

Review 9.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

10.  Prokinetic benzamides stimulate peristaltic activity in the isolated guinea pig ileum by activation of 5-HT4 receptors.

Authors:  K H Buchheit; T Buhl
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

View more
  10 in total

Review 1.  Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Authors:  Norman Stockbridge; Joel Morganroth; Rashmi R Shah; Christine Garnett
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 2.  Efficacy and tolerability of cisapride in children.

Authors:  Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice.

Authors:  Z Desta; K T Kivistö; J J Lilja; J T Backman; N Soukhova; P J Neuvonen; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

5.  Evidence of impaired cisapride metabolism in neonates.

Authors:  J M Tréluyer; E Rey; M Sonnier; G Pons; T Cresteil
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

6.  The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.

Authors:  Hugo Vanden Bossche; Jannie Ausma; Hilde Bohets; Karen Vermuyten; Gustaaf Willemsens; Patrick Marichal; Lieven Meerpoel; Frank Odds; Marcel Borgers
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil.

Authors:  Peter H Bui; Arnulfo Quesada; Adrian Handforth; Oliver Hankinson
Journal:  Drug Metab Dispos       Date:  2008-04-14       Impact factor: 3.922

8.  Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.

Authors:  Felipe T Lee-Montiel; Alexander Laemmle; Verena Charwat; Laure Dumont; Caleb S Lee; Nathaniel Huebsch; Hideaki Okochi; Matthew J Hancock; Brian Siemons; Steven C Boggess; Ishan Goswami; Evan W Miller; Holger Willenbring; Kevin E Healy
Journal:  Front Pharmacol       Date:  2021-05-07       Impact factor: 5.810

Review 9.  Adverse reactions of Amiodarone.

Authors:  Ruben Ml Colunga Biancatelli; Viviana Congedo; Leonardo Calvosa; Marco Ciacciarelli; Alessandro Polidoro; Luigi Iuliano
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

10.  Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.

Authors:  D Zhou; K Bui; M Sostek; N Al-Huniti
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.